Homepage
Author:
Design Therapeutics, Inc.
Posted Date:
May 28, 2026
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics, Inc.
May 28, 2026
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
Design Therapeutics, Inc.
May 22, 2026
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Design Therapeutics, Inc.
May 22, 2026
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Design Therapeutics, Inc.
April 28, 2026
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Design Therapeutics, Inc.
March 9, 2026
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc.
February 18, 2026
